Literature DB >> 21934233

Leukemic phase of anaplastic lymphoma kinase positive, anaplastic large cell lymphoma.

Vijaya S Gadage1, P G Subramanian, Komal S Galani, Kunal K Sehgal, Sachin P Johari, Vijay S Ghogale, Y Badrinath, K Ashok, Sumeet Gujral.   

Abstract

Anaplastic large cell lymphoma (ALCL) is a distinct type of CD30+ T/null-cell non-Hodgkin's lymphoma that frequently involves nodal and extranodal sites. The presence of leukemic phase in ALCL is extremely rare and occurs exclusively with ALK1-positive ALCL. We describe two patients with ALK1-positive ALCL who developed a leukemic phase with rapid progression of the disease. Immunophenotypic pattern assessed on peripheral blood by flow cytometry revealed CD45, CD30, and CD25 positivity in both cases but NPM-ALK1 was expressed in only one case. Both patients developed leukemic phase as a terminal event of the disease and we share the immunophenotypic features of both cases.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21934233     DOI: 10.4103/0377-4929.85108

Source DB:  PubMed          Journal:  Indian J Pathol Microbiol        ISSN: 0377-4929            Impact factor:   0.740


  3 in total

1.  Small cell variant of anaplastic large cell lymphoma with leukemic presentation: a diagnostic challenge.

Authors:  Tomás Zecchini Barrese; Carlo Sagramoso; Francesco Bacci; Elena Sabattini
Journal:  Rev Bras Hematol Hemoter       Date:  2017-06-27

2.  Acute leukemic phase of anaplastic lymphoma kinase-anaplastic large cell lymphoma: A case report and review of the literature.

Authors:  Huai-Feng Zhang; Yan Guo
Journal:  World J Clin Cases       Date:  2020-11-06       Impact factor: 1.337

3.  Immunophenotypic shifts during minimal residual evaluation in a case of leukemic form of anaplastic large cell lymphoma ALK.

Authors:  Maria Clara Canellas; Enrico Bruno-Riscarolli; Cristiane S Ferreira-Facio; Daiana V Lopes-Alves; Vitor D Botafogo; Deborah Sutter; Roberia M Pontes; Marcelo G P Land; Cristiane Bedran Milito; Elaine Sobral da Costa
Journal:  Cancer Rep (Hoboken)       Date:  2021-08-11
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.